(Q43048280)

12 November 2017

Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans (English)

1 reference

12 November 2017

0 references

1 reference

Butt AA

1

1 reference

12 November 2017

Khan UA

2

1 reference

12 November 2017

McGinnis KA

3

1 reference

12 November 2017

Skanderson M

4

1 reference

12 November 2017

Kent Kwoh C

5

1 reference

12 November 2017

1 December 2007

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

14

1 reference

12 November 2017

12

1 reference

12 November 2017

890-896

1 reference

The natural history of hepatitis C virus infection: host, viral, and environmental factors

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Reasons for non-treatment of hepatitis C in veterans in care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Prevalence of hepatitis C virus seropositivity among hospitalized US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Veterans aging cohort three-site study (VACS 3): overview and description

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00885.X

10.1111/J.1365-2893.2007.00885.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference